Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
The identification of the PD-1 receptor by Tasuku Honjo and CTLA-4 by James Ellison marked the beginning of the study of new regulatory pathways activating the immune response. The term “immune checkpoints” was introduced to denote the system of inhibitory mechanisms that include these proteins. The...
Saved in:
Main Authors: | A. V. Chetveryakov, V. L. Tsepelev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Scientific Сentre for Family Health and Human Reproduction Problems
2021-10-01
|
Series: | Acta Biomedica Scientifica |
Subjects: | |
Online Access: | https://www.actabiomedica.ru/jour/article/view/2982 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy
by: Laura Denisa Dragu, et al.
Published: (2025-07-01) -
Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy
by: Haozhe Piao, et al.
Published: (2025-07-01) -
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01) -
Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review
by: Xinyi Zhang, et al.
Published: (2025-07-01) -
Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)